610 Pancreatic Cancer Clinical Trials Recruiting Now (July 2026): Daraxonrasib, KRAS, Claudin 18.2, ADC, Immunotherapy

Last updated: July 1, 2026

🔔 Post-ASCO 2026 (May 29 – June 2) update: KRAS-mutant PDAC is now the most active Phase 3 oncology space outside breast cancer. Three new KRAS G12D Phase 3 trials launched in July 2026: NCT07621718 zoldonrasib (RMC-9805) + chemo 1L metastatic, NCT07522073 INCB161734 + chemo 1L KRAS G12D, and NCT07409272 setidegrasib (ASP3082) KRAS G12D degrader + mFOLFIRINOX/NALIRIFOX. The daraxonrasib (RMC-6236, pan-RAS(ON)) Phase 3 PDAC program — RASolute 302 NCT07491445 (1L metastatic) and RASolute 304 NCT07252232 (resected adjuvant) — was the ASCO 2026 plenary headline. Two more new entrants: NCT07562152 atebimetinib + GnP (MEK), NCT07490301 telisotuzumab adizutecan + FOLFOX (c-MET ADC). Cross-link: KRAS Inhibitors hub for the cross-cancer view; CLDN18.2 hub for the CLDN18.2 ADC + CAR-T landscape.

Current Clinical Trial Landscape

Active research areas in 2026:

KRAS-targeted therapies (~65 trials) — pan-RAS inhibitors (daraxonrasib/RMC-6236 now in both first-line metastatic and adjuvant resected Phase 3), G12D-specific (RMC-9805, HRS-4642), G12C inhibitors (sotorasib), G12V TCR-T cell therapy, KRAS neoantigen vaccines
Immunotherapy combinations (~100 trials) — PD-1/PD-L1 + VEGF bispecifics (ivonescimab Phase 3 PDAC), CD47 checkpoint (AK117), stromal-targeting combinations to overcome immunotherapy resistance
BRCA/PALB2-directed (~26 trials) — platinum-based regimens, PARP inhibitors (olaparib (Lynparza) — POLO trial maintenance landmark), plus niraparib (Zejula) + ipilimumab in metastatic pancreatic (NCT06747845 Phase 2 PARPi + checkpoint combination), homologous recombination deficiency-guided therapy. See the PARP Inhibitors mechanism hub.
Claudin 18.2-targeted — IBI343 ADC (G-HOPE-002 Phase 3), dual-target CAR-T (mesothelin + CLDN18.2)
HER2-amplified PDAC (~2-3%) — eligible for trastuzumab deruxtecan (T-DXd) pan-tumor and HER2 ADC trials
Supportive care / cachexia — ponsegromab (GDF-15 antagonist, Pfizer Phase 3 in PDAC cachexia)
Novel delivery — tumor treating fields (TTFields), intra-arterial chemotherapy, ctDNA-guided adjuvant therapy

Standard of care: For resectable disease: surgery followed by adjuvant modified FOLFIRINOX (6 months) or gemcitabine + capecitabine. Neoadjuvant chemotherapy increasingly used for borderline resectable. For locally advanced: FOLFIRINOX or gemcitabine/nab-paclitaxel, with radiation in selected cases. For metastatic: FOLFIRINOX (fit patients) or gemcitabine/nab-paclitaxel. Olaparib maintenance for germline BRCA1/2-mutated patients with platinum-stable/responsive disease (POLO trial). Second-line: nanoliposomal irinotecan + 5-FU/leucovorin (NAPOLI-1).

Key Biomarkers for Trial Eligibility

Molecular profiling is essential — over 25% of pancreatic cancer patients have actionable mutations:

KRAS mutation type — present in ~90% of PDAC. The specific variant matters for targeted therapy:
- KRAS G12D (~40%) — most common; RMC-9805, HRS-4642 trials
- KRAS G12V (~30%) — IX001 TCR-T cell therapy trial
- KRAS G12C (~1-2%) — sotorasib (FDA-approved for NSCLC, trials in PDAC)
- KRAS G12R (~15%) — pan-RAS inhibitors (daraxonrasib/RMC-6236)
BRCA1/2 or PALB2 mutation — germline mutations in ~5-7%. Eligible for platinum-based chemo (better response), PARP inhibitors (olaparib), and specific combination trials.
MSI-H / dMMR — rare (~1-2%) but eligible for pembrolizumab (FDA-approved for all MSI-H cancers). Dramatic responses possible.
Claudin 18.2 (CLDN18.2) expression — expressed in ~60% of PDAC. Target for IBI343 ADC (Phase 3) and CAR-T therapy.
NTRK fusion — very rare (<1%) but druggable with larotrectinib or entrectinib (FDA-approved).
HER2 amplification — rare (~2-3%) but eligible for trastuzumab deruxtecan and other HER2 ADC trials.
ctDNA (circulating tumor DNA) — increasingly used to guide adjuvant therapy decisions. Several trials use ctDNA to identify patients who may benefit from additional treatment after surgery.

Know your KRAS variant and BRCA status? Get matched to pancreatic cancer trials in minutes.

Find Matching Trials

Recruiting Trials by Treatment Setting

First-Line Metastatic

FOLFIRINOX or gemcitabine/nab-paclitaxel remain standard. Trials add novel agents:

Pan-RAS / KRAS-directed first-line:
- NCT07491445 - RASolute 302: Daraxonrasib (RMC-6236) monotherapy and daraxonrasib + Gemcitabine/Nab-paclitaxel vs SOC in first-line metastatic PDAC (Phase 3, the registrational metastatic-setting trial of the pan-RAS(ON) inhibitor)
- NCT07562152 - Atebimetinib + Gemcitabine/Nab-paclitaxel as first-line treatment in metastatic PDAC (Phase 3 MEK inhibitor combo)
IO + chemotherapy:
- NCT06953999 - Ivonescimab (PD-1/VEGF bispecific) + Chemo ± AK117 (CD47) in metastatic PDAC (Phase 3)
- NCT06361888 - Surufatinib + Camrelizumab + Nab-paclitaxel + Gemcitabine (Phase 2/3)
Novel combinations:
- NCT06079346 - OT-101 (TGF-β2 antisense) + mFOLFIRINOX (Phase 3)
- NCT07076121 - MountainTAP-30: BMS-986504 + Nab-paclitaxel + Gemcitabine vs Placebo (Phase 3)
- NCT05254171 - Nab-paclitaxel + Gemcitabine ± SBP-101 (polyamine inhibitor) (Phase 3)
- NCT07079228 - QLS31905 + Chemo vs Placebo + Chemo (Phase 3)
BRCA/PALB2-mutated:
- NCT06783140 - NABPLAGEM vs Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2-mutated PDAC (Phase 3)
- NCT06095141 - Cisplatin for PDAC with homologous recombination deficiency (Phase 3)

Second-Line / Pretreated

NCT07066098 - G-HOPE-002: IBI343 (Claudin 18.2 ADC) vs Placebo in CLDN18.2+ pretreated PDAC (Phase 3)
NCT06897644 - Gemcitabine + Nab-paclitaxel switch maintenance vs continuation mFOLFIRINOX (Phase 3)
NCT01954992 - Glufosfamide vs 5-FU in second-line metastatic PDAC (Phase 3)
NCT06998940 - Chemo ± Panitumumab for unresectable/metastatic PDAC (Phase 3)

Resectable / Borderline Resectable / Locally Advanced

Neoadjuvant:
- NCT06714604 - Standard vs prolonged neoadjuvant chemo before surgery for BR/LAPC (Phase 3)
- NCT05529940 - NeoFOL-R: Perioperative vs adjuvant FOLFIRINOX in resectable PDAC (Phase 3)
- NCT05268692 - Neoadjuvant chemo followed by GS and GnP (Phase 3)
- NCT07081360 - Neoadjuvant vs upfront surgery for resectable PDAC (Phase 3)
Adjuvant:
- NCT07252232 - RASolute 304: Daraxonrasib (RMC-6236, pan-RAS(ON)) vs SOC observation in resected PDAC (Phase 3)
- NCT07044453 - Risk-adapted adjuvant chemo guided by tumor stage after neoadjuvant (Phase 3)
- NCT06427447 - ADJUPANC: Adjuvant chemoradiotherapy vs chemo for PDAC (Phase 3)
- NCT07632118 - Radiotherapy + GX regimen as adjuvant therapy for high-risk patients after pancreatic cancer surgery (Phase 3, activated 2026-06-09 — RT + gemcitabine/capecitabine (GX) intensification for high-recurrence-risk resected PDAC; positive-margin / node-positive / high-CA19-9 population)
- NCT04969731 - Immuncell-LC (autologous immune cells) + Gemcitabine adjuvant (Phase 3)
Locally advanced:
- NCT03257033 - Intra-arterial Gemcitabine vs IV Gem/Nab-pac after RT for LAPC (Phase 3)
- NCT06958328 - Higher dose radiation for locally advanced PDAC (Phase 3)
- NCT06250972 - Radiotherapy for CA19-9-elevated advanced PDAC (Phase 3)

KRAS-Targeted Therapies (~65 trials)

Over 90% of pancreatic cancers have KRAS mutations. Once considered undruggable, KRAS is now the most active Phase 3 space in PDAC: daraxonrasib (RMC-6236, pan-RAS(ON)) in both 1L metastatic and adjuvant-resected Phase 3; zoldonrasib (RMC-9805) and INCB161734 KRAS G12D RAS(ON) Phase 3; setidegrasib (ASP3082) KRAS G12D degrader Phase 3; HRS-4642 G12D for borderline resectable; NCI's KRAS G12V TCR-T (NCT04146298). For the cross-cancer KRAS class (sotorasib + adagrasib + calderasib + olomorasib + glecirasib + garsorasib in NSCLC + CRC), see the KRAS Inhibitors hub.

Pan-RAS (multi-selective):
- NCT07491445 - RASolute 302: Daraxonrasib ± Gemcitabine/Nab-paclitaxel in first-line metastatic PDAC (Phase 3)
- NCT07252232 - RASolute 304: Daraxonrasib adjuvant in resected PDAC (Phase 3)
- NCT05379985 - RMC-6236 in advanced solid tumors with RAS mutations (Phase 1/2)
KRAS G12D-specific (Phase 3 wave, July 2026):
- NCT07621718 - Zoldonrasib (RMC-9805) + chemo vs Placebo + chemo as first-line treatment in metastatic PDAC with KRAS G12D (Phase 3, the first KRAS G12D RAS(ON) Phase 3 in PDAC)
- NCT07522073 - INCB161734 + chemo in previously-untreated KRAS G12D-mutated metastatic PDAC (Phase 3, Incyte KRAS G12D)
- NCT07262567 - GFH375 vs chemotherapy in KRAS G12D-mutant metastatic PDAC (Phase 3, activated 2026-06-27 — GenFleet KRAS G12D-selective inhibitor, fourth Phase 3 in the G12D PDAC wave)
- NCT07409272 - Setidegrasib (ASP3082) + mFOLFIRINOX or NALIRIFOX in metastatic PDAC (Phase 3, KRAS G12D degrader — PROTAC-like mechanism, distinct from RAS(ON) inhibitors)
- NCT06040541 - RMC-9805 in KRAS G12D-mutant solid tumors (Phase 1, basis for the NCT07621718 Phase 3)
- NCT07240766 - HRS-4642 + Nimotuzumab + Chemo for borderline resectable PDAC with KRAS G12D (Phase 2)
KRAS G12V TCR-T cell therapy:
- NCT04146298 - NCI-sponsored autologous TCR-T cell therapy targeting mutated KRAS G12V (Phase 1/2, pan-tumor; PDAC + CRC + NSCLC cohorts)
- NCT06898385 - IX001 TCR-T for advanced PDAC with KRAS G12V mutation (Phase 1)
KRAS vaccines:
- NCT07353645 - KRAS neoantigen nanovaccine adjuvant for CRC/PDAC (Phase 1/2)
- NCT06411691 - KRAS-targeted vaccine + Balstilimab + Botensilimab for PDAC (Phase 1)

Novel Approaches

Claudin 18.2-targeted: IBI343 (ADC, G-HOPE-002 Phase 3), dual-target CAR-T (mesothelin + CLDN18.2), NCT07066995. For the cross-cancer CLDN18.2 landscape (zolbetuximab gastric SPOTLIGHT/GLOW, CT041 CAR-T, AZD0901, sonesitatug vedotin), see the CLDN18.2 hub.
c-MET ADC (new Phase 3 entry): NCT07490301 - Telisotuzumab Adizutecan + FOLFOX in metastatic PDAC (Phase 2/3, c-MET-directed ADC class entering PDAC)
HER2-targeted (HER2-amplified PDAC): trastuzumab deruxtecan (T-DXd) pan-tumor HER2 ADC program; HER2 expression occurs in ~2-3% of PDAC and qualifies for T-DXd and other HER2 ADC trials. See the HER2 ADCs hub for cross-cancer ADC landscape.
Tumor treating fields: NCT05653453 - TTFields + Gemcitabine + Nab-paclitaxel (Phase 3)
Cancer cachexia (supportive care): NCT06989437 - Ponsegromab (GDF-15 antagonist) in PDAC patients with cachexia (Phase 3) — first dedicated cachexia Phase 3 for PDAC
ctDNA-guided: NCT05482516 - Novel therapies in ctDNA-positive GI cancers
Intra-arterial chemotherapy: Direct hepatic artery or tumor infusion to overcome poor drug delivery in PDAC

Showing selected notable trials. View all 610 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find pancreatic cancer clinical trials I'm eligible for?

Enter your pancreatic cancer details into ClinTrialFinder — including KRAS mutation type (G12D, G12V, G12C, G12R), BRCA/PALB2 status, disease stage (resectable, borderline, locally advanced, metastatic), and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.

What pancreatic cancer trials are currently recruiting?

There are 610 recruiting interventional trials for pancreatic cancer in July 2026 including 49 Phase 3 studies. KRAS-mutant PDAC is now the most active Phase 3 space outside breast cancer: pan-RAS daraxonrasib (RMC-6236) in 1L metastatic (RASolute 302 NCT07491445) and adjuvant resected (RASolute 304 NCT07252232) Phase 3; three new KRAS G12D Phase 3 entrants in July 2026 (zoldonrasib NCT07621718, INCB161734 NCT07522073, setidegrasib NCT07409272); HRS-4642 G12D borderline resectable; NCI's KRAS G12V TCR-T NCT04146298; KRAS vaccines. Other active fronts: Claudin 18.2 ADCs (IBI343 G-HOPE-002 NCT07066098) and CAR-T (see CLDN18.2 hub); ivonescimab PD-1/VEGF bispecific NCT06953999 (see bispec IO hub); telisotuzumab adizutecan c-MET ADC NCT07490301; BRCA/PALB2-directed PARP and platinum; MSI-H immunotherapy; ponsegromab for cachexia; ctDNA-guided adjuvant therapy. See the KRAS Inhibitors hub for the full pan-RAS landscape.

Should I get molecular profiling for pancreatic cancer?

Yes — comprehensive genomic profiling is strongly recommended for all pancreatic cancer patients. Over 25% have actionable mutations: BRCA1/2 or PALB2 (~5-7%) qualify for PARP inhibitors and platinum-based therapy, MSI-H (~1-2%) responds dramatically to immunotherapy, NTRK fusions are druggable with FDA-approved agents, and knowing your specific KRAS variant (G12D, G12V, G12C) determines which targeted therapy trials you're eligible for.

Are KRAS-mutant pancreatic cancers now treatable with targeted therapy?

KRAS — once considered "undruggable" — is now a therapeutic target. Daraxonrasib (RMC-6236), a pan-RAS(ON) inhibitor, is in two registrational Phase 3 trials in PDAC simultaneously: first-line metastatic monotherapy and combination with gemcitabine/nab-paclitaxel (RASolute 302, NCT07491445), and adjuvant after surgical resection (RASolute 304, NCT07252232). RMC-9805 targets KRAS G12D specifically (the most common variant in pancreatic cancer, ~40%). KRAS G12C can be targeted with sotorasib. KRAS vaccines and TCR-T cell therapy targeting G12V are also in clinical trials. Knowing your specific KRAS variant is essential.

Find Pancreatic Cancer Trials Matched to Your Situation

Enter your KRAS mutation type, BRCA status, and disease stage to get AI-matched trial results in minutes.